June 4, 2020 / 10:36 PM / a month ago

BRIEF-Adamas Announces FDA Filing Acceptance Of SNDA To Modify The Indication Statement For Gocovri® To Include Treatment For Parkinson’S Disease Patients Receiving Levodopa And Experiencing Off Episodes

June 4 (Reuters) - Adamas Pharmaceuticals Inc:

* ADAMAS ANNOUNCES FDA FILING ACCEPTANCE OF SNDA TO MODIFY THE INDICATION STATEMENT FOR GOCOVRI® TO INCLUDE TREATMENT FOR PARKINSON’S DISEASE PATIENTS RECEIVING LEVODOPA AND EXPERIENCING OFF EPISODES

* ADAMAS PHARMACEUTICALS - ANTICIPATED PDUFA ACTION DATE IS FEBRUARY 1, 2021 FOR GOCOVRI SNDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below